Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Thermo Fisher Scientific has launched AcroMetrix Coronavirus 2019 (Covid-19) RNA Control to monitor and validate Covid-19 molecular diagnostic tests.

The new quality control product is developed by formulating synthetic RNA transcripts that contain unique N, S, E and Orf1ab regions of SARS-CoV-2 genome into a proprietary buffer.

Thermo Fisher’s latest product launch is aimed at fighting the coronavirus outbreak.

As necessary for the test, the RNA is set for reverse transcription, PCR amplification and detection.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The kit contains two SARS-CoV-2 specific RNA vials at the concentration that will result in low-positive and ultra-low positive in commonly used Covid-19 nucleic acid testing methods that are based on Polymerase Chain Reaction (PCR).

Thermo Fisher speciality diagnostics business senior vice-president and president Gianluca Pettiti said: “Our team is committed to providing innovative solutions to support our customers with better diagnostic tools.

“The AcroMetrix Coronavirus 2019 (Covid-19) RNA Control is a positive control to aid in validating and monitoring Covid-19 diagnostic tests.”

The new RNA control is available as a Research Use Only (RUO) product globally and is not intended for clinical use.

Last month, the company announced that it expects to produce up to five million testing kits during April, to detect nucleic acid from the SARS-CoV-2 virus that causes Covid-19 disease.

Currently, the company has 1.5 million tests available to ship under the emergency use authorisation (EUA) label.

The test runs on Applied Biosystems TaqPath Assay technology and delivers patient results within four hours from when a lab receives a sample.